Conference Correspondent

Conference Correspondent

Variability in surface antigen expression patterns correlated to different outcomes in patients with normal karyotype acute myeloid leukemia (AML).

Timed sequential administration of busulfan may represent a more efficacious approach to the treatment of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Allogeneic stem-cell transplant was found to improve patient outcomes, regardless of age and induction regimen.

The PD-1 inhibitor nivolumab, in combination with azacytidine, may represent an effective treatment option for some patients with relapsed acute myeloid leukemia (AML).

In this analysis, researchers evaluate whether daratumumab can further reduce minimal residual disease when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.

Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.

In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Payers have expressed concern about the rising costs of combination therapies in multiple myeloma. In an effort to address these potential concerns, a budget impact model was developed to estimate the 3-year costs of adding elotuzumab in combination with lenalidomide and dexamethasone to a health plan’s formulary.

Risk stratification tools are used to estimate survival expectations and help to guide treatment decisions after first relapse in multiple myeloma. European researchers have developed a new stratification tool consisting of 4 distinct dimensions that are used to characterize risk of survival.

Immunotherapy is being studied as a potential treatment approach in a variety of hematologic malignancies. Here, researchers present the findings of a phase 2 trial evaluating pembrolizumab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Page 12 of 19
Results 111 - 120 of 190
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME